ALT 0.00% 0.5¢ analytica limited

This could have ramifications for sexual function as a 'side...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 15,831 Posts.
    lightbulb Created with Sketch. 216
    This could have ramifications for sexual function as a 'side effect' as it focuses on the pelvic floor area IMO
    The mind boggles

    "Case Studies of PeriCoach published in Peer Reviewed Urology Journal 19 May 2016: Brisbane, Australia – Analytica Ltd (ASX:ALT) manufacturer of the PeriCoach® System is pleased to announce the publication of case studies describing pelvic floor training with PeriCoach in the Urologic Nursing Journal of the US Society of Urologic Nurses and Associates. Clinical support and publication in a leading peer review journal is a significant milestone for the Company and is a direct reflection of executing its strategy to obtain clinical evidence of PeriCoach. The journal articles are authored by US Nurse Practitioner (NP) Julie Starr and Physiotherapist (PT) Beth Shelley. The articles are based on two separate case studies which were conducted to demonstrate the efficacy and ease of the use PeriCoach in the treatment of common pelvic floor dysfunctions such as urinary incontinence and pelvic organ prolapse, as well as the emotional and lifestyle benefits of restoring pelvic floor strength. These outcomes are a direct result of the Company’s US Early Adopter Program in which leaders in pelvic health were encouraged to utilise PeriCoach in practice with patients currently engaged in a pelvic floor rehabilitation program. In both cases studies, PeriCoach was demonstrated to be an easy-to-use, affordable and effective non-surgical home training option for strengthening pelvic floor muscles and decreasing symptoms of UI and POP. • The case reported by Julie Starr, APRN, FNP, Women's Health Care, University of Missouri Healthcare, describes the experience of an athletic 37-year-old woman seeking treatment for symptoms of stress urinary incontinence. • The Case reported by Beth Shelley, PT, DPT, WCS, BCB-PMD, describes the experience of a 66-year-old woman with Pelvic Organ Prolapse (POP) and urinary incontinence who performed at-home PFME with the assistance of PeriCoach. Analytica CEO Geoff Daly said – “The publication of these case studies is a great endorsement for PeriCoach and is our greatest differentiator to other players in the incontinence market. It demonstrates that we are on the right path with our strategy in becoming the trusted solution for incontinence for clinicians and women.” PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the US by prescription. Shareholders can access both case studies via - http://www.pericoach.com/wp-content/uploads/2016/05/unj_ma16_05_STARR_FINAL.pdf http://www.pericoach.com/wp-content/uploads/2016/05/unj_ma16_04_BShelly_FINAL.pdf
 
watchlist Created with Sketch. Add ALT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.